Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.35
SCMP's Cash to Debt is ranked higher than
69% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SCMP: 1.35 )
SCMP' s 10-Year Cash to Debt Range
Min: 0.86   Max: No Debt
Current: 1.35

Equity to Asset 0.50
SCMP's Equity to Asset is ranked higher than
61% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SCMP: 0.50 )
SCMP' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.82
Current: 0.5

-0.21
0.82
Interest Coverage 4.86
SCMP's Interest Coverage is ranked higher than
53% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. SCMP: 4.86 )
SCMP' s 10-Year Interest Coverage Range
Min: 3.55   Max: 9999.99
Current: 4.86

3.55
9999.99
F-Score: 6
Z-Score: 6.41
M-Score: 4.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.47
SCMP's Operating margin (%) is ranked higher than
80% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. SCMP: 12.47 )
SCMP' s 10-Year Operating margin (%) Range
Min: -903.97   Max: 28.03
Current: 12.47

-903.97
28.03
Net-margin (%) 5.37
SCMP's Net-margin (%) is ranked higher than
71% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. SCMP: 5.37 )
SCMP' s 10-Year Net-margin (%) Range
Min: -906.55   Max: 41.39
Current: 5.37

-906.55
41.39
ROE (%) 8.73
SCMP's ROE (%) is ranked higher than
79% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. SCMP: 8.73 )
SCMP' s 10-Year ROE (%) Range
Min: -130.02   Max: 154.11
Current: 8.73

-130.02
154.11
ROA (%) 3.93
SCMP's ROA (%) is ranked higher than
74% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. SCMP: 3.93 )
SCMP' s 10-Year ROA (%) Range
Min: -83.83   Max: 37.89
Current: 3.93

-83.83
37.89
ROC (Joel Greenblatt) (%) 32.63
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. SCMP: 32.63 )
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19500.5   Max: 5678.08
Current: 32.63

-19500.5
5678.08
Revenue Growth (3Y)(%) 12.50
SCMP's Revenue Growth (3Y)(%) is ranked higher than
81% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. SCMP: 12.50 )
SCMP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.1   Max: 127
Current: 12.5

-21.1
127
» SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SCMP Guru Trades in Q3 2013

Jim Simons 127,800 sh (-45.62%)
» More
Q4 2013

SCMP Guru Trades in Q4 2013

Jim Simons 36,000 sh (-71.83%)
» More
Q1 2014

SCMP Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

SCMP Guru Trades in Q3 2014

Paul Tudor Jones 12,761 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 103.60
SCMP's P/E(ttm) is ranked higher than
68% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.00 vs. SCMP: 103.60 )
SCMP' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 115.73
Current: 103.6

5.44
115.73
P/B 8.38
SCMP's P/B is ranked higher than
55% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. SCMP: 8.38 )
SCMP' s 10-Year P/B Range
Min: 1.18   Max: 9.99
Current: 8.38

1.18
9.99
P/S 5.77
SCMP's P/S is ranked higher than
65% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. SCMP: 5.77 )
SCMP' s 10-Year P/S Range
Min: 1.2   Max: 7.19
Current: 5.77

1.2
7.19
PFCF 64.62
SCMP's PFCF is ranked higher than
83% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCMP: 64.62 )
SCMP' s 10-Year PFCF Range
Min: 3.68   Max: 346.4
Current: 64.62

3.68
346.4
EV-to-EBIT 45.92
SCMP's EV-to-EBIT is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. SCMP: 45.92 )
SCMP' s 10-Year EV-to-EBIT Range
Min: -1008.9   Max: 66.7
Current: 45.92

-1008.9
66.7
Current Ratio 2.83
SCMP's Current Ratio is ranked higher than
75% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. SCMP: 2.83 )
SCMP' s 10-Year Current Ratio Range
Min: 1.27   Max: 9.21
Current: 2.83

1.27
9.21
Quick Ratio 2.82
SCMP's Quick Ratio is ranked higher than
80% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SCMP: 2.82 )
SCMP' s 10-Year Quick Ratio Range
Min: 1.27   Max: 9.21
Current: 2.82

1.27
9.21

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 54.28
SCMP's Price/Net Current Asset Value is ranked higher than
78% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCMP: 54.28 )
SCMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.01   Max: 26
Current: 54.28

2.01
26
Price/Tangible Book 8.43
SCMP's Price/Tangible Book is ranked higher than
62% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. SCMP: 8.43 )
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.32   Max: 11.29
Current: 8.43

1.32
11.29
Price/DCF (Projected) 27.70
SCMP's Price/DCF (Projected) is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. SCMP: 27.70 )
SCMP' s 10-Year Price/DCF (Projected) Range
Min: 0.95   Max: 13.27
Current: 27.7

0.95
13.27
Price/Median PS Value 1.90
SCMP's Price/Median PS Value is ranked higher than
60% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. SCMP: 1.90 )
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.71   Max: 2.69
Current: 1.9

0.71
2.69
Price/Graham Number 6.41
SCMP's Price/Graham Number is ranked higher than
70% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.05 vs. SCMP: 6.41 )
SCMP' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 5.32
Current: 6.41

0.95
5.32
Earnings Yield (Greenblatt) 2.20
SCMP's Earnings Yield (Greenblatt) is ranked higher than
72% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SCMP: 2.20 )
SCMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 108.7
Current: 2.2

1.5
108.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:R3A.Germany,
Sucampo Pharmaceuticals, Inc. was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
comment on SCMP Mar 06 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 
Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 06 2009 

More From Our Partners
One Stock Chart Trick You Should All Know - Investment Ideas Dec 16 2014 - ZACKS

More From Other Websites
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 15 2014
Sucampo Appoints John H. Johnson to Board of Directors Dec 15 2014
Sucampo Appoints John H. Johnson to Board of Directors Dec 15 2014
Flexion Therapeutics (FLXN) Worth Watching: Stock Up 9.2% Dec 15 2014
Dipexium (DPRX) Worth Watching: Stock Moves 7.8% Higher Dec 11 2014
Can The Uptrend Continue for Sucampo Pharmaceuticals (SCMP)? Dec 09 2014
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% Dec 08 2014
Why Sucampo Pharmaceuticals (SCMP) Stock Might be a Great Pick Dec 08 2014
Avanir to be acquired by Otsuka for $3.5 Billion, Shares Up Dec 03 2014
Avanir Pharmaceuticals, Inc. (AVNR) in Focus: Stock Soars 12.8% Dec 03 2014
Flamel Technologies (FLML) in Focus: Stock Rises 8.4% Dec 03 2014
Valeant's Onexton Gel Gets FDA Approval for Acne Dec 01 2014
Bio Blast Pharma (ORPN) in Focus: Stock Moves Up 26.6% Nov 28 2014
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Nov 25 2014
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 26th Annual Piper Jaffray... Nov 25 2014
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 26th Annual Piper Jaffray... Nov 25 2014
SUCAMPO PHARMACEUTICALS, INC. Financials Nov 14 2014
Flamel Technologies (FLML) in Focus: Stock Rises 11% Nov 14 2014
Can The Uptrend Continue for Sucampo Pharmaceuticals (SCMP)? Nov 14 2014
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK